Good evening

Eugia Pharma Receives USFDA Approval for Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL

Published: January 24, 2022

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL.

Indications for this product include:

  • Secondary hyperparathyroidism in adult patients with CKD on dialysis.


Refer to package insert for full prescribing information.